Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials

Trial Profile

Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Dinutuximab (Primary) ; Interleukin-2; Isotretinoin; Sargramostim
  • Indications Neuroblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 08 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 13 Oct 2016 Planned number of patients changed from 10 to 25.
    • 13 Oct 2016 Planned End Date changed from 1 May 2017 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top